ReviewA review on the effect of COVID-19 in type 2 asthma and its management
Graphical abstract
Keywords
COVID-19
SARS-CoV-2
Type-2 asthma
Cytokines
Inflammation
T-cells
Abbreviations
SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus-2
COVID-19
Coronavirus Disease-19
NIH
National Institutes of Health
NSAIDs
Nonsteroidal Anti-Inflammatory Drug
ACE inhibitors
Angiotensin-Converting Enzyme Inhibitors
AHR
Airway Hyper-Responsiveness
TSLP
Thymic stromal lymphopoietin
NK Cells
Natural Killer cells
FVC
Forced Vital Capacity
PEF
Peak Expiratory Flow Rate
FEV1
Forced Expiratory Volume In The First Second
FeNO
Fractional Exhaled Nitric Oxide
STAT-6
Signal Transducer And Activator Of Transcription-6
JAK-2/STAT-5
Janus Kinase-2/Signal Transducer And Activator Of Transcription-5
M-CSF
Macrophage Colony-Stimulating Factor
POSTN
Periostin Gene
ORF
Open Reading Frames
RBD
Receptor-Binding Domain
TMPRSS2
Transmembrane Protease, Serine 2
Rdrp
RNA-Dependent RNA Polymerase
HLA
Human Leukocyte Antigen
CDC
Centres For Disease Control And Prevention
HRV
Human Rhinovirus
AERD
Aspirin-Exacerbated Respiratory Disease
FRC
Functional Residual Capacity
ERV
Expiratory Reserve Volume
TNF-α
Tumor Necrosis Factor-Alpha
ACOS
Asthma-COPD Overlap Syndrome
COPD
Chronic Obstructive Pulmonary Disease
GINA
Global Initiative For Asthma
FRU
First Referral Units
HFNC
High Flow Nasal Cannula
DPPC
Dipalmitoyl Phosphatidyl Choline
NRDS
Neonatal Respiratory Distress Syndrome
SP
Surfactant Protein
HRCT
High-Resolution Computed Tomography
Cited by (0)
- 1
Authors with equal contribution.
© 2020 Elsevier B.V. All rights reserved.